| 1.92 0.04 (2.13%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.48 | 1-year : | 2.72 |
| Resists | First : | 2.12 | Second : | 2.32 |
| Pivot price | 1.99  |
|||
| Supports | First : | 1.79 | Second : | 1.49 |
| MAs | MA(5) : | 1.9  |
MA(20) : | 2.05 |
| MA(100) : | 2.22 |
MA(250) : | 2.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 22.4 |
| RSI | RSI(14): 32.8 |
|||
| 52-week | High : | 3.44 | Low : | 1.79 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XBIT ] has closed above bottom band by 20.8%. Bollinger Bands are 158.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.96 - 1.98 | 1.98 - 1.98 |
| Low: | 1.84 - 1.85 | 1.85 - 1.86 |
| Close: | 1.85 - 1.87 | 1.87 - 1.88 |
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Sat, 31 Oct 2026
XBiotech Inc. (XBIT) Seasonal returns chart - Yahoo Finance Australia
Thu, 29 Oct 2026
Insider Spends US$711k Buying More Shares In XBiotech - Simply Wall St
Wed, 28 Oct 2026
XBiotech (NASDAQ:XBIT) Director John Simard Acquires 368,524 Shares of Company Stock - MarketBeat
Wed, 28 Oct 2026
A co-CEO receives stock options with a $1.85 exercise price from XBiotech (XBIT). - Stock Titan
Wed, 28 Oct 2026
Co-CEO Jan-Paul Simard held no securities before an option grant at XBiotech (XBIT). - Stock Titan
Wed, 28 Oct 2026
At $1.93 a share, director John Simard buys 368,524 XBiotech (XBIT) shares. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 36.8 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 328 (K) |
| Shares Short P.Month | 343 (K) |
| EPS | -1.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | -30 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -41 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.4 |
| Dividend | 2.5 |
| Forward Dividend | 0 |
| Dividend Yield | 134% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|